By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on GPCR's oral GLP-1 candidate, with concerns about execution risk in Phase 3 trials and competition from established players, but also potential for acquisition by Big Pharma if Phase 3 data is strong.
Risk: High failure risk in Phase 3 trials due to severe GI tolerability issues and competition from established rivals like Lilly and Novo.
Opportunity: Potential acquisition by Big Pharma if Phase 3 data shows significant weight loss with manageable dropout rates.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
ACT Capital Management sold 38,500 shares of Structure Therapeutics in the first quarter; the estimated transaction value was $2.63 million based on Q1 2026 average prices.
The quarter-end position value decreased by $2.68 million, reflecting both the sale and stock price movement.
The transaction represented 2.07% of reported 13F assets under management (AUM).
On May 8, 2026, ACT Capital Management reported selling all 38,500 shares of Structure Therapeutics (NASDAQ:GPCR), an estimated $2.63 million trade based on quarterly average pricing.
According to its SEC filing dated May 8, 2026, ACT Capital Management fully exited its position in Structure Therapeutics during the first quarter. The fund sold all 38,500 shares, with the estimated transaction value at $2.63 million based on the average closing price for the quarter. The net position change, which includes both trading and price effects, was a $2.68 million decrease. The fund now reports no shares in the company.
NASDAQ: TGTX: $8.27 million (6.5% of AUM)
As of May 7, 2026, shares of Structure Therapeutics were priced at $39.15, up 47% over the past year and outperforming the S&P 500 by about 17 percentage points.
| Metric | Value | |---|---| | Price (as of market close May 7, 2026) | $39.15 | | Market Capitalization | $2.8 billion | | Net Income (TTM) | ($141.2 million) |
Structure Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of novel oral small-molecule therapeutics for chronic diseases with significant unmet needs. The company leverages expertise in G-protein-coupled receptor (GPCR) drug targets to advance candidates in metabolic, pulmonary, and cardiovascular indications. Its strategy centers on innovation in oral drug design, aiming to provide differentiated therapies in competitive, high-growth markets.
Structure Therapeutics shares have climbed about 47% over the past year, and ACT Capital appears to have decided the easier money may already have been made, especially with biotech volatility still elevated across the GLP-1 space.
That said, the company’s underlying momentum remains hard to ignore. Just this week, Structure reported positive Phase 2 data for aleniglipron, its oral GLP-1 drug candidate, showing up to 16.3% placebo-adjusted weight loss at 44 weeks. Management said the efficacy potentially compares favorably with injectable GLP-1 therapies and remains on track to launch a Phase 3 program in the third quarter.
The balance sheet also gives the company room to execute. Structure ended the quarter with roughly $1.5 billion in cash, cash equivalents, and short-term investments, which management says should fund operations through the end of 2028.
With all this in mind, this sale ultimately looks less like a loss of confidence in Structure Therapeutics and more like a disciplined exit after a massive run in obesity-drug names. Hiccups in data releases could challenge the stock, but it’s impossible to ignore the momentum in the obesity drug market.
Before you buy stock in Structure Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Structure Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 10, 2026. *
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and Krystal Biotech. The Motley Fool recommends TG Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The fund's exit is a routine portfolio rebalancing event that fails to negate the company's strong clinical data and robust cash position."
The exit of a $2.6M position by ACT Capital is statistically noise, representing only 2% of their AUM. Investors should ignore the 'insider selling' narrative and focus on the $1.5 billion cash runway through 2028. With GPCR's oral GLP-1 candidate showing a 16.3% placebo-adjusted weight loss, the valuation of $2.8 billion remains attractive relative to the massive obesity market TAM. The stock's 47% run-up is justified by clinical progress rather than speculative hype. I view this as a 'buy the dip' scenario; the real risk isn't a small fund rebalancing, but the execution risk inherent in transitioning from Phase 2 to a pivotal Phase 3 trial in a crowded competitive landscape.
The oral GLP-1 market is becoming a 'winner-take-most' space where late-movers like GPCR may struggle to gain market share against entrenched incumbents like Eli Lilly and Novo Nordisk.
"GPCR's stretched $2.8B valuation leaves no margin for error on Phase 3 tolerability in a GLP-1 arena littered with oral failures."
GPCR's $2.8B market cap (at $39.15/share) embeds flawless Phase 3 success for oral GLP-1 aleniglipron, fresh off topline Phase 2 data (16.3% placebo-adjusted weight loss at 44 weeks), despite $141M TTM losses and zero revenue. ACT Capital's exit of 38,500 shares ($2.6M, just 2% of AUM) is trivial noise—especially from a fund rotating into stable names like CVX ($15.5M) and XOM ($11.9M) while retaining biotechs like KRYS. Article glosses over oral GLP-1 pitfalls: severe GI tolerability issues have derailed rivals (e.g., Pfizer's danuglipron). Phase 3 Q3 start looms with high failure risk in crowded field (Lilly, Novo, Viking); hiccups could crater stock to cash-backed ~$20/share ($1.5B runway to 2028).
Aleniglipron's weight loss rivals injectables with oral upside, backed by $1.5B cash for dilution-free execution through 2028, potentially capturing share in $100B+ obesity market.
"A clinical-stage biotech with zero revenue, negative earnings, and a single Phase 2 candidate doesn't justify a $2.8B valuation even with $1.5B cash—ACT's exit reflects skepticism about Phase 3 execution risk that the article downplays as mere profit-taking."
ACT Capital's exit is being framed as profit-taking after a 47% run, but the real signal is buried: a $2.6M position represents only 2.07% of their AUM—this wasn't a core holding. More concerning: GPCR trades at $2.8B market cap with -$141M net income (TTM) and relies entirely on Phase 2 data for an oral GLP-1 candidate. The article cherry-picks the 16.3% weight-loss number but omits: (1) how this compares head-to-head in Phase 3 against Novo/Eli Lilly's proven injectables, (2) oral bioavailability challenges in GLP-1 space remain unsolved at scale, and (3) $1.5B cash runway through 2028 sounds long until you model burn rates for Phase 3 + commercial prep. The fund's exit timing—right after positive data—suggests they don't believe the risk/reward justifies holding through execution risk.
If aleniglipron's Phase 3 succeeds and oral delivery proves superior to injectables, GPCR could be worth $8-12B within 24 months, making this exit a costly mistake by ACT regardless of near-term volatility.
"Structure Therapeutics could re-rate meaningfully if aleniglipron proves superior in Phase 3 and the company sustains its cash runway, despite substantial data and execution risk."
ACT Capital's exit is small (38,500 shares, about $2.63 million, 2.07% of AUM) and not a fundamental verdict. Structure's 47% Y/Y gain and roughly $1.5 billion on-hand should support a Phase 3 path for aleniglipron, potentially a meaningful upside if the data hold. However, the company is clinical-stage with a large net loss and faces a crowded GLP-1 landscape, competition from injectables, and regulatory risk. Data surprises or delays could erase momentum quickly, despite the cash runway into 2028. The 13F move mainly highlights risk management by managers, not a bearish rebuke of the science.
The strongest counterpoint is that the ACT exit may reflect growing concern about the durability of aleniglipron's advantages and the high bar to Phase 3 success; plus, Structure faces intense competition and fundraising risk if milestones slip.
"GPCR's cash position acts as a strategic buffer that forces potential acquirers to pay a premium rather than exploit a distressed balance sheet."
Claude, you’re missing the M&A angle. While you focus on the $141M burn, you ignore that Big Pharma is desperate for oral GLP-1 assets to defend their injectable franchises. GPCR isn't building a commercial team; they are building a target for acquisition. The $1.5B cash runway isn't just for Phase 3—it’s leverage that prevents a 'fire sale' valuation. If the Phase 3 data holds, the exit isn't a mistake; it's just a fund rebalancing portfolios.
"Big Pharma's advanced oral GLP-1 pipelines diminish GPCR's acquisition appeal, amplifying standalone execution risks."
Gemini, your M&A thesis overlooks Lilly's orforglipron (Phase 3, 14.7% weight loss, milder GI effects) and Novo's oral amycretin—both ahead with deeper pockets for commercialization. GPCR isn't a 'must-have' asset; Big Pharma can wait for Phase 3 proof or let it falter on manufacturing scale-up. Unmentioned risk: aleniglipron's 44-week data masks potential dropout rates >30% in Phase 3, eroding efficacy signals.
"Phase 3 dropout rates and efficacy durability are the real gatekeepers; M&A optionality only exists if clinical data holds."
Grok flags dropout rates >30% in Phase 3—that's the real tell. But nobody's quantified what 'flawless execution' actually means here. If aleniglipron hits 18% weight loss with <15% dropout in Phase 3, it's genuinely differentiated vs. Lilly's 14.7%. The M&A angle (Gemini) only works if Phase 3 succeeds; if it doesn't, $1.5B cash becomes a slow bleed, not leverage. The burn rate math matters more than runway length.
"Phase 3 success alone won’t guarantee a premium M&A exit; deal dynamics, manufacturing, and payer economics will largely determine GPCR's upside."
Gemini’s M&A thesis hinges on Phase 3 success and a Big Pharma premium, but it ignores practical hurdles: scalable manufacturing, payer economics, and competition that can deter a premium buyout or condense value into milestones. Even with strong data, Lilly/Novo could opt for licensing or wait for additional proof, meaning GPCR’s upside may hinge more on data than a looming buyout. The exit path isn’t guaranteed.
The panel is divided on GPCR's oral GLP-1 candidate, with concerns about execution risk in Phase 3 trials and competition from established players, but also potential for acquisition by Big Pharma if Phase 3 data is strong.
Potential acquisition by Big Pharma if Phase 3 data shows significant weight loss with manageable dropout rates.
High failure risk in Phase 3 trials due to severe GI tolerability issues and competition from established rivals like Lilly and Novo.